We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Zynrelef

News List

Heron Therapeutics Announces FDA Approval of an Indication Expansion for Zynrelef for Postoperative Pain Management Drugs
December 14, 2021
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs...
Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients E firstwordpharma
July 29, 2021
Heron Therapeutics, Inc. today announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled
FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain drugs
May 24, 2021
HRTX today announced that FDA has approved Zynrelef extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy
Zynrelef Anesthetic Receives FDA Approval contractpharma
May 18, 2021
Lifecore will manufacture the new innovative drug for treatment of postoperative pain.